DRUG
carbetocin
Oxycontin analogue
Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section
Status
Completed
Phase
Phase 4
Enrollment
300
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
to compare effectiveness and tolerability of carbetocin versus syntometrine in prevention of Postpartum hemorrhage after cesarean section
Full detailed description
A double blind randomized study conducted on 450 pregnant subjected randomly either to single 100 μg IV dose of carbetocin (150 women) or combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal. Prevention of postpartum haemorrhage (PPH) after cesarean section (CS) had been evaluated by measurement of drop of Hemoglobin and hematocrit, incidence of PPH and number of subjects needed additional oxytocic
Interventions
Treatment arms and agents.
DRUG
Syntometrine
Uterotonins
Timeline
From registration to results.
First posted
Jan 24, 2014
Study start
Jun 2014
Primary completion
Dec 2015
Study completion
Dec 2015
Results posted
Not reported
Registry updated
Jun 24, 2021
Outcomes
What the study measures.
Primary outcomes
prevention of post partum hemorrhage after CS
Time frame · 24 hours
Number of participants experienced postpartum hemorrhage
Secondary outcomes
side effects of drugs used
Time frame · 24 hours
Number of subjects experienced Hemodynamic changes (blood pressure , pulse and respiratory rate ) , GIT side effects as nausea , vomiting and metallic taste, Vasomotor effects as flushing, headache , itching
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 39 Years
- Sex
- FEMALE
- Healthy volunteers
- Yes
Inclusion Criteria: * All participants are at 37 - 40 weeks of gestational age * Noncomplicated pregnancy. Exclusion Criteria: * Participants with placenta previa * Patients with coagulopathy * preeclamptic women * known sensitivity to oxytocin or methergine were excluded
Study locations
1 registered sites.
Egypt. Showing up to 24 locations stored in the fast local snapshot.
Ahmed Maged
Cairo, Egypt
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Carbetocin.
NCT IDStudyPhase / statusEnrollmentUpdated
The Efficacy of Carbitocin in Reduction of Blood Loss During Myomectomy
Alex Ekwueme Federal University Teaching Hospital · Blood Loss, Surgical
Early Phase 1
Not yet recruiting
900
2026-07
Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial
Mansoura University · Postpartum Hemorrhage · Uterine Atony
Phase 4
Not yet recruiting
332
2026-06
Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage
Sheba Medical Center · Postpartum Hemorrhage · Twin Pregnancy
Phase 4
Recruiting
120
2026-05
Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Postpartum Hemorrhage
Not applicable
Recruiting
32
2026-04
Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Post Partum Hemorrhage
Not applicable
Recruiting
160
2026-04
Effect of Co-administration of Carbetocin and Calcium Chloride on Uterine Tone in Patients Undergoing Elective Cesarean Delivery
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Postpartum Hemorrhage (Primary)
Not applicable
Recruiting
120
2026-04
Comparison of the Effect of Carbetocin Versus Oxytocin in the Prevention of Postpartum Hemorrhage After Emergency Caesarean Section in Antenatal Low-risk Patients
Ankara Etlik City Hospital · Postpartum Hemorrhage \(PPH\)
Not applicable
Completed
300
2026-02
Carbetocin Myocardium Trial 2014 Part 2
Oslo University Hospital · Pregnancy Complications
Phase 4
Completed
240
2026-02
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.